Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Future Oncol
; 12(17): 2001-8, 2016 Sep.
Article
en En
| MEDLINE
| ID: mdl-27255717
ABSTRACT
AIM:
To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients.METHODS:
68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur(®) Serum HER2 test. CellSearch System was performed for CTC quantification.RESULTS:
HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival.CONCLUSION:
ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Biomarcadores de Tumor
/
Receptor ErbB-2
/
Células Neoplásicas Circulantes
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Italia